<p>Arcellx（纳斯达克代码：ACLX - 获取免费报告）的股票在 Cantor Fitzgerald 发布的报告中被研究分析师重申了 “中性” 评级，报告于周三发布，Benzinga 报道。</p>
<p>其他一些股票分析师也对 ACLX 发表了评论。富国银行将 Arcellx 的股票评级从 “增持” 下调至 “持平”，并设定了 115.00 美元的目标价。在 2 月 23 日的报告中，加拿大和信集团为 Arcellx 的股票设定了 115.00 美元的目标价。在 2 月 23 日的报告中，Evercore 也为 Arcellx 的股票设定了 115.00 美元的目标价。罗伯特·W·贝尔德在 2 月 23 日的报告中重申了 “中性” 评级，并将 Arcellx 的目标价从 106.00 美元上调至 115.00 美元。最后，瑞银集团在 2 月 24 日的研究报告中将 Arcellx 的股票评级从 “买入” 下调至 “中性”，并将其目标价从 100.00 美元上调至 115.00 美元。一位股票研究分析师给予该股票 “强烈买入” 评级，一位给予 “买入” 评级，十六位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价为 111.87 美元。</p>
<p><strong>查看我们最新的 ACLX 股票报告</strong></p>
<h2>Arcellx 股票表现</h2>
<p>在周三的午盘交易中，纳斯达克：ACLX 的股票保持在 115.07 美元平稳交易。该公司交易了 14,666,200 股，相比其平均交易量 1,498,960 股。该公司的市值为 67.3 亿美元，市盈率为-28.27，贝塔值为 0.25。该公司的 50 日移动平均价格为 111.71 美元，200 日移动平均价格为 87.66 美元。Arcellx 的 1 年最低价为 47.86 美元，1 年最高价为 115.13 美元。</p>
<p>Arcellx（纳斯达克：ACLX - 获取免费报告）最后一次发布财报是在 2 月 26 日，星期四。该公司报告每股收益为（1.01 美元），符合市场共识预期（1.01 美元）。该季度的营业收入为 165 万美元，而分析师预期为 1340 万美元。Arcellx 的净利润率为-1,027.26%，股本回报率为-55.42%。平均而言，股票研究分析师预测 Arcellx 在当前财政年度的每股收益为-2.91。</p>
<h2>Arcellx 的内部买卖</h2>
<p>在相关消息中，内部人士 Rami Elghandour 于 2 月 27 日星期五出售了 89,916 股公司的股票。该股票以 113.92 美元的平均价格出售，总交易额为 10,243,230.72 美元。出售完成后，内部人士持有 276,051 股公司股票，价值 31,447,729.92 美元。这代表其持股比例减少了 24.57%。该交易在向证券交易委员会的备案中披露，相关信息可通过此链接访问。8.35% 的股票目前由公司内部人士持有。</p>
<h2>机构资金流入和流出</h2>
<p>一些对冲基金和其他机构投资者最近买卖了 ACLX 的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Arcellx 的股份增加了 5.1%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 28,753 股公司股票，价值 1,893,000 美元，在此期间又购买了 1,390 股。Empowered Funds LLC 在第一季度获得了 Arcellx 的新头寸，价值约为 1,768,000 美元。Intech Investment Management LLC 在第一季度将其在 Arcellx 的股份增加了 27.7%。Intech Investment Management LLC 目前持有 21,967 股公司股票，价值 1,441,000 美元，在此期间又购买了 4,760 股。保诚金融公司在第二季度将其在 Arcellx 的股份增加了 49.2%。保诚金融公司目前持有 4,900 股公司股票，价值 323,000 美元，在此期间又购买了 1,615 股。最后，挪威银行在第二季度获得了 Arcellx 的新头寸，价值约为 739,000 美元。96.03% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Arcellx</h2>
<p>（获取免费报告）</p>
<p>Arcellx, Inc（纳斯达克：ACLX）是一家临床阶段的生物制药公司，专注于发现、开发和商业化下一代细胞疗法，用于肿瘤和自身免疫疾病。该公司的专有 ARC-SparX™平台旨在实现对细胞表面受体激活的精确控制，并提高采用细胞疗法的安全性、有效性和持久性。利用这一技术，Arcellx 对免疫细胞进行工程改造，赋予其可互换的抗原结合域，以针对多种与疾病相关的标记。</p>
<p>该公司的产品管线包括多个在血液恶性肿瘤和实体肿瘤领域的全资项目，处于不同的临床前和临床开发阶段。</p>
<h2>相关文章</h2>
<ul>
<li>我们更看好的五只股票，而不是 Arcellx</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Arcellx 吗？</h2>
<p>在你考虑 Arcellx 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场注意到之前……而 Arcellx 并不在名单上。</p>
<p>虽然 Arcellx 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ACLX

<p>Cantor Fitzgerald 重申了对 Arcellx（NASDAQ: ACLX）股票的 “中性” 评级。其他分析师也发表了看法，富国银行将该股票评级下调至 “持平”，并设定了 115 美元的目标价。Canaccord Genuity 和 Evercore 也设定了相同的目标价。该股票目前交易价格为 115.07 美元，平均评级为 “持有”，目标价为 111.87 美元。Arcellx 报告每股收益为（1.01 美元），符合预期，收入为 165 万美元，显著低于预期。内部人士 Rami Elghandour 出售了股票，减少了其持股比例 24.57%</p>

<p>Arcellx (NASDAQ:ACLX - Get Free Report)'s stock had its &#34;neutral&#34; rating reaffirmed by research analysts at Cantor Fitzgerald in a report released on Wednesday,Benzinga reports.</p>
<div class="lb-trans"><p>Arcellx（纳斯达克代码：ACLX - 获取免费报告）的股票在 Cantor Fitzgerald 发布的报告中被研究分析师重申了 “中性” 评级，报告于周三发布，Benzinga 报道。</p>
</div><p>A number of other equities analysts have also commented on ACLX. Wells Fargo &amp; Company lowered shares of Arcellx from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and set a $115.00 price objective on the stock. in a report on Monday, February 23rd. Canaccord Genuity Group set a $115.00 price objective on shares of Arcellx in a report on Monday, February 23rd. Evercore set a $115.00 price objective on shares of Arcellx in a report on Monday, February 23rd. Robert W. Baird reiterated a &#34;neutral&#34; rating and issued a $115.00 price objective (up from $106.00) on shares of Arcellx in a report on Monday, February 23rd. Finally, UBS Group downgraded shares of Arcellx from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and boosted their target price for the stock from $100.00 to $115.00 in a research report on Tuesday, February 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of &#34;Hold&#34; and an average price target of $111.87.</p>
<div class="lb-trans"><p>其他一些股票分析师也对 ACLX 发表了评论。富国银行将 Arcellx 的股票评级从 “增持” 下调至 “持平”，并设定了 115.00 美元的目标价。在 2 月 23 日的报告中，加拿大和信集团为 Arcellx 的股票设定了 115.00 美元的目标价。在 2 月 23 日的报告中，Evercore 也为 Arcellx 的股票设定了 115.00 美元的目标价。罗伯特·W·贝尔德在 2 月 23 日的报告中重申了 “中性” 评级，并将 Arcellx 的目标价从 106.00 美元上调至 115.00 美元。最后，瑞银集团在 2 月 24 日的研究报告中将 Arcellx 的股票评级从 “买入” 下调至 “中性”，并将其目标价从 100.00 美元上调至 115.00 美元。一位股票研究分析师给予该股票 “强烈买入” 评级，一位给予 “买入” 评级，十六位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “持有”，平均目标价为 111.87 美元。</p>
</div><p><strong>View Our Latest Stock Report on ACLX</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 ACLX 股票报告</strong></p>
</div><h2>Arcellx Stock Performance</h2>
<div class="lb-trans"><h2>Arcellx 股票表现</h2>
</div><p>Shares of NASDAQ:ACLX remained flat at $115.07 during midday trading on Wednesday. 14,666,200 shares of the company traded hands, compared to its average volume of 1,498,960. The firm has a market capitalization of $6.73 billion, a P/E ratio of -28.27 and a beta of 0.25. The firm has a fifty day moving average price of $111.71 and a two-hundred day moving average price of $87.66. Arcellx has a 1-year low of $47.86 and a 1-year high of $115.13.</p>
<div class="lb-trans"><p>在周三的午盘交易中，纳斯达克：ACLX 的股票保持在 115.07 美元平稳交易。该公司交易了 14,666,200 股，相比其平均交易量 1,498,960 股。该公司的市值为 67.3 亿美元，市盈率为-28.27，贝塔值为 0.25。该公司的 50 日移动平均价格为 111.71 美元，200 日移动平均价格为 87.66 美元。Arcellx 的 1 年最低价为 47.86 美元，1 年最高价为 115.13 美元。</p>
</div><p>Arcellx (NASDAQ:ACLX - Get Free Report) last posted its earnings results on Thursday, February 26th. The company reported ($1.01) earnings per share for the quarter, meeting the consensus estimate of ($1.01). The business had revenue of $1.65 million for the quarter, compared to analyst estimates of $13.40 million. Arcellx had a negative net margin of 1,027.26% and a negative return on equity of 55.42%. On average, equities research analysts forecast that Arcellx will post -2.91 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Arcellx（纳斯达克：ACLX - 获取免费报告）最后一次发布财报是在 2 月 26 日，星期四。该公司报告每股收益为（1.01 美元），符合市场共识预期（1.01 美元）。该季度的营业收入为 165 万美元，而分析师预期为 1340 万美元。Arcellx 的净利润率为-1,027.26%，股本回报率为-55.42%。平均而言，股票研究分析师预测 Arcellx 在当前财政年度的每股收益为-2.91。</p>
</div><h2>Insider Buying and Selling at Arcellx</h2>
<div class="lb-trans"><h2>Arcellx 的内部买卖</h2>
</div><p>In related news, insider Rami Elghandour sold 89,916 shares of the business's stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $113.92, for a total transaction of $10,243,230.72. Following the completion of the sale, the insider owned 276,051 shares of the company's stock, valued at $31,447,729.92. This represents a 24.57% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. 8.35% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Rami Elghandour 于 2 月 27 日星期五出售了 89,916 股公司的股票。该股票以 113.92 美元的平均价格出售，总交易额为 10,243,230.72 美元。出售完成后，内部人士持有 276,051 股公司股票，价值 31,447,729.92 美元。这代表其持股比例减少了 24.57%。该交易在向证券交易委员会的备案中披露，相关信息可通过此链接访问。8.35% 的股票目前由公司内部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently bought and sold shares of ACLX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Arcellx by 5.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,753 shares of the company's stock valued at $1,893,000 after purchasing an additional 1,390 shares during the period. Empowered Funds LLC acquired a new position in Arcellx during the 1st quarter valued at about $1,768,000. Intech Investment Management LLC boosted its stake in Arcellx by 27.7% during the 1st quarter. Intech Investment Management LLC now owns 21,967 shares of the company's stock valued at $1,441,000 after purchasing an additional 4,760 shares during the period. Prudential Financial Inc. boosted its stake in Arcellx by 49.2% during the 2nd quarter. Prudential Financial Inc. now owns 4,900 shares of the company's stock valued at $323,000 after purchasing an additional 1,615 shares during the period. Finally, Norges Bank acquired a new position in Arcellx during the 2nd quarter valued at about $739,000. 96.03% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近买卖了 ACLX 的股票。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Arcellx 的股份增加了 5.1%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.目前持有 28,753 股公司股票，价值 1,893,000 美元，在此期间又购买了 1,390 股。Empowered Funds LLC 在第一季度获得了 Arcellx 的新头寸，价值约为 1,768,000 美元。Intech Investment Management LLC 在第一季度将其在 Arcellx 的股份增加了 27.7%。Intech Investment Management LLC 目前持有 21,967 股公司股票，价值 1,441,000 美元，在此期间又购买了 4,760 股。保诚金融公司在第二季度将其在 Arcellx 的股份增加了 49.2%。保诚金融公司目前持有 4,900 股公司股票，价值 323,000 美元，在此期间又购买了 1,615 股。最后，挪威银行在第二季度获得了 Arcellx 的新头寸，价值约为 739,000 美元。96.03% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Arcellx</h2>
<div class="lb-trans"><h2>关于 Arcellx</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arcellx, Inc NASDAQ: ACLX is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.</p>
<div class="lb-trans"><p>Arcellx, Inc（纳斯达克：ACLX）是一家临床阶段的生物制药公司，专注于发现、开发和商业化下一代细胞疗法，用于肿瘤和自身免疫疾病。该公司的专有 ARC-SparX™平台旨在实现对细胞表面受体激活的精确控制，并提高采用细胞疗法的安全性、有效性和持久性。利用这一技术，Arcellx 对免疫细胞进行工程改造，赋予其可互换的抗原结合域，以针对多种与疾病相关的标记。</p>
</div><p>The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个在血液恶性肿瘤和实体肿瘤领域的全资项目，处于不同的临床前和临床开发阶段。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相关文章</h2>
</div><ul>
<li>Five stocks we like better than Arcellx</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Arcellx</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=ACLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arcellx Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Arcellx 吗？</h2>
</div><p>Before you consider Arcellx, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Arcellx 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在购买，以便在更广泛的市场注意到之前……而 Arcellx 并不在名单上。</p>
</div><p>While Arcellx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arcellx 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Arcellx（ACLX）的 “中性” 评级在 Cantor Fitzgerald 被重申